吉西他滨联合替吉奥化疗在胰腺癌根治术后患者中的应用效果

Application effect of gemcitabine combined with tegafur chemotherapy in patients after radical resection of pancreatic cancer

目的研究吉西他滨联合替吉奥化疗在胰腺癌根治术后患者中的应用价值。方法 70例胰腺癌根治术后患者,根据随机数字表法分为对照组和观察组,每组35例。对照组患者单纯采用吉西他滨化疗,观察组患者采用吉西他滨联合替吉奥化疗。比较两组患者生活质量、不良反应发生情况。结果化疗前,两组患者生活质量评分比较差异无统计学意义(P>0.05);化疗后第1、4、8天,观察组患者生活质量评分分别为(79.32±1.34)、(85.05±1.25)、(93.42±1.58)分,均显著高于对照组的(72.61±3.12)、(73.45±1.26)、(80.53±1.44)分,差异具有统计学意义(P<0.05);观察组患者不良反应发生率为5.71%,明显低于对照组的25.71%,差异具有统计学意义(P<0.05)。结论采用吉西他滨联合替吉奥化疗治疗胰腺癌根治术后患者,可以明显降低不良反应发生率,提高治疗的效果,值得推广应用。

Objective To study the application value of gemcitabine combined with tegafur chemotherapy in patients after radical resection of pancreatic cancer. Methods A total of 70 patients after radical resection of pancreatic cancer were divided by random number table into control group and observation group, with 35 cases in each group. The control group was treated with gemcitabine for chemotherapy, and the observation group was treated with gemcitabine combined with tegafur for chemotherapy. The quality of life and occurrence of adverse reactions between the two groups was compared. Results Before chemotherapy, both groups had no statistically significant difference in quality of life score(P>0.05). After 1, 4 and 8 days of chemotherapy, the observation group obviously higher quality of life score respectively as(79.32±1.34),(85.05±1.25) and(93.42±1.58) points than(72.61±3.12),(73.45±1.26) and(80.53±1.44) points in the control group, and their difference was statistically significant(P<0.05). The observation group had obviously lower incidence of adverse reactions as 5.71% than 25.71% in the control group, and the difference was statistically significant(P<0.05). Conclusion Combination of gemcitabine and tegafur chemotherapy in treating patients after radical resection of pancreatic cancer can obviously lower the incidence of adverse reactions and improve the treatment effect. It is worthy of promotion and application.